Company: MIRM
Filing Date: 2025-05-30
Form Type: 8-K
Source: 0001759425-25-000034
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-30
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 29, 2025, Mirum Pharmaceuticals, Inc. (the “ Company”) held its 2025 Annual Meeting of Stockholders (the “ Annual Meeting”). As of April 3, 2025, the record date for the Annual Meeting,49,454,336 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

                         Votes For                      Votes Withheld                      Broker Non-Votes                 
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Laura Brege                           17,968,766                          18,167,097                            7,017,835  
  Michael Grey                          30,777,470                           5,358,393                            7,017,835  
  Christopher Peetz                     35,980,278                             155,585                            7,017,835  

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

   Votes For      Votes Against      Abstentions  
 ──────────────────────────────────────────────────
  43,115,134             19,188           19,376  

Proposal 3. Advisory Vote on Executive Compensation

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting. The final voting results are as follows:

   Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────
  34,671,826          1,455,143            8,894             7,017,835  

SIGNATURES

Pursuant to the requirements of the